Are Adult Stem Cells a Bust?
Opponents of research on embryonic stem cells have insisted that adult stem cells are a therapeutically superior and ethically more acceptable alternative. However, a new report in Nature finds that adult stem cells may not be the panacea that the bioconservative movement had hoped.
Is the US pharmaceuticals industry losing its way?
The EU generally looks to the US as its model for pharmaceuticals innovation. But US companies are showing signs of vulnerability due to competition from generics and a lack of new ‘blockbuster’ drugs.
U.S. drug companies curb supplies to Canadian exporters
As the political fight over drug imports into the United States intensifies, several top industry executives say that they have been effective in denying supplies to Canadian pharmacies that ship to America.
The next big thing is…
According to the most recent MoneyTree Survey, a report put together by PricewaterhouseCoopers, Thomson Venture Economics and the National Venture Capital Association, which tracks venture capital investments, biotech and medical equipment firms are really the next big thing …
Although overall VC funding in the third quarter dipped 8 percent from the second quarter, investments in so-called life science firms increased 14 percent.
Pharmaceutical Makers Turn To CRM
After years of blockbuster medications that literally change the way their customers live, drugmakers are facing a period of uncertainty as the cost of developing the next big thing grows and the discovery pipeline shrinks. Many pharmaceutical companies are turning to customer-relationship-management technology as a means to squeeze revenue from existing products and prime the market for what’s to come.
Fog Begins to Lift with Q3 Biotech Numbers
Certain market indicators for 2003�s third quarter suggest that at least some investors and analysts are anticipating more boom, less doom.
India emerges as new drug trial hot spot
Biotech entrepreneurs see Indian clinical trials � which can cut costs by 60 percent � as the difference between success and slow death.
Who’s Going To Pay For Global Health?
The amazingly swift global response to the SARS outbreak earlier this year demonstrated once and for all that it is possible for countries to join forces and fight epidemics quickly and effectively. So, shouldn’t the same apply to the true pandemics � AIDS, malaria and tuberculosis? Indeed it should � but global strategies to fight these scourges are just now starting to come together.
Seeking a Prescription for Biogenerics
No U.S. laws allow for generic versions of off-patent biotech medicines. Several forces are now working to change that
Why Merck Missed the Mark
S&P’s Herman Saftlas talks about the Street’s reaction to the drug giant’s disappointing earnings report and what the future may hold